Reading...
Play button
Play button
Use LEFT and RIGHT arrow keys to navigate between flashcards;
Use UP and DOWN arrow keys to flip the card;
H to show hint;
A reads text to speech;
53 Cards in this Set
- Front
- Back
|
acute leukemia
|
immature cells
|
|
|
chronic leukemia
|
mature cells
|
|
|
myelogenous
|
monocyte
|
|
|
leukocytic
|
B and T cell
|
|
|
ALL age?
|
up to 10yrs
|
|
|
CLL age?
|
65+
|
|
|
ALL marker?
|
CD10
|
|
|
ALL cytogenics?
|
Philadelphia translocation
BCR-Abl with IL-3R = proliferation |
|
|
ALL treatment?
|
highly sensitive to chemo
Imatinib (TK inhib) BMT |
|
|
CLL marker?
|
CD5
|
|
|
CLL diagnosis
|
CD5
WBC 90% lymphocytes |
|
|
CLL cytogenetics
|
bcl2oncogene
13q deletion |
|
|
CLL treatment
|
predisolone
chemo monoclonal Ab therapy |
|
|
AML age
|
65
|
|
|
AML diagnosis
|
Auer rods
anemia thrombocytopenia neutropenia |
|
|
AML treatment
|
chemo
BMT |
|
|
CML age
|
40-50
|
|
|
CML diagnosis
|
Splenomegaly
philadelphia chromosome increased granulocytes and platelets |
|
|
CML treatment
|
chemo
BMT imatinib |
|
|
Hodgkins Lymphoma (HD) diagnosis
|
one or cluster of lymphnodes
CD15 (Le X) often EBV |
|
|
HD treatment
|
radiotherapy
ABVD combined chemo |
|
|
HD % of cancers
|
1
|
|
|
NHL % of cancers
|
4
|
|
|
Folicular B cell Lymphoma age
|
60 - 65
|
|
|
Folicular B cell Lymphoma characteristics?
|
indolent
Bcl2 half transform into agressive tumors |
|
|
Folicular B cell Lymphoma treatment
|
retuximab
ibitrumab tositumab |
|
|
diffuse large B cell lymphoma age
|
all, but usually older
|
|
|
diffuse large B cell lymphoma characteristics
|
aggressive
extranodal |
|
|
diffuse large B cell lymphoma treatment
|
intensive combination chemo
|
|
|
Multiple Myeloma characteristics
|
B cell tumor that secrets monoclonal Ig called paraptoteins
bone marrow |
|
|
MM age?
|
50+
|
|
|
MM diagnostics
|
2 of:
inc in abnormal looking plasma cells osteoperosis or lytic lesions of bone paraproteins bence jones proteins in the urine |
|
|
MM clinical
|
Bone pain
hypercalcemia Ab defic and inc infection anemia renal probs |
|
|
MM treatment
|
mainly palliative
|
|
|
TSA's
|
viral proteins
mutations in oncogenes |
|
|
TAA's
|
CEA
AFP HER2 PSA |
|
|
CEA
|
carcenoembryonic antigen
overexpressed in most cancers, but very useful for monitering colon cancer after treatment |
|
|
cytokines used for cancer immunotherapy
|
INF - inc MHC I
IL-2 - inc activity of NK and CTL and macs |
|
|
Tumor infiltrating lymphocytes (TIL)
|
T-cells surrounding tumors that are incubated with IL-2
|
|
|
Lymphokine activated killer cells (LAKs)
|
taken from blood and hyped on IL-2, NKs in specific
|
|
|
patients with defects in humoral immunity usually present with?
|
pyogenic infections
|
|
|
patients with cell mediated immunodeficiency often present with
|
viral, intracellular, and opportunistic infections
|
|
|
primary immunodeficiency
|
defects in WBC
defects in compliment |
|
|
secondary immunodeficiency
|
aquired:
malnutrition drugs cancers infections |
|
|
Chediak-Higashi synd
|
defect in LYST
impropor lysosome and granule trafficking |
|
|
SCID
|
deficient CD132 (y chain of cytokine receptors)
ADA deficiency (adenosine deaminase) defic JAK3 defic RAG |
|
|
Wiscott aldrich syndrome defects
|
x linked defect in the WASp protein
no growth of hematoploetic cells |
|
|
Wiscott aldrich synd symptoms
|
bleeding (thrombocytopenia)
recurrent bacterial viral and fungal infections Eczema |
|
|
Ataxia-talangectasia (AT) defects
|
recessive disorder of ATM (prot kinase for DNA repair)
|
|
|
AT symptoms
|
abnormal gait (cerebellar degradation)
dilated blood vessles recurrent sinus and resp infections |
|
|
job syndrome defects
|
dominant or recessive mutation of STST3
|
|
|
job synd diagnostics
|
no IL-12
high Th2 no phagocytosis deficient DTH |
|
|
DeGeorge synd
|
no thymus or parathyroid (hypocalcemia)
deletion of 21 q11 2 chromosome |
